Enterprise Value
-21.83M
Cash
56.55M
Avg Qtr Burn
-10.94M
Short % of Float
0.14%
Insider Ownership
0.39%
Institutional Own.
43.32%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ME-344 (Mitochondrial Inhibitor) + bevacizumab Details Cancer, Solid tumor/s, Colorectal cancer | Phase 1b Update | |
Voruciclib (CDK Inhibitor) +/- venetoclax Details B-cell malignancies, Acute myeloid leukemia, Cancer | Phase 1 Data readout | |
Zandelisib (Oral P13K Delta Inhibitor) Details B-cell malignancies | Failed Discontinued | |
Zandelisib (Oral P13K Delta Inhibitor) Details Follicular lymphoma | Failed Discontinued | |
Zandelisib (Oral P13K Delta Inhibitor) Details B-cell malignancies | Failed Discontinued |